Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01147809

Enrollment

130

Registered

2010-06-22

Start date

2010-06-30

Completion date

2015-03-31

Last updated

2016-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopaenia

Keywords

Solid Tumor, Eltrombopag, chemotherapy-induced thrombocytopenia, Thrombocytopenia

Brief summary

The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I of the study will examine safety and tolerability of various doses of eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful benefit(s) to thrombocytopenic patients by improving platelet numbers.

Interventions

DRUGEltrombopag olamine

thrombopoietin receptor agonist

OTHERPlacebo

Placebo tablets with no active pharmaceutical ingredient

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Inclusion Criteria Subjects eligible for enrolment in Phase I and II of the study must meet all of the following criteria: * Signed written informed consent. * Age ≥ 18 years. * Subjects with confirmed solid tumor and scheduled to receive at least two cycles of either gemcitabine monotherapy OR gemcitabine in combination with carboplatin or cisplatin at the same dosages and schedule in the study. Novel anticancer agents (e.g. bevacizumab, erlotinib) may be allowed if considered a standard treatment by the investigator. Subjects with only ONE current diagnosis of primary solid tumor will be allowed into the study. * Note: For patients scheduled to receive any novel anticancer agents (e.g. bevacizumab, erlotinib), consultation and approval from the GSK medical monitor should occur before the subject is enrolled into the study. * Life expectancy of at least 3 months, in the opinion of the investigator. * ECOG-Zubrod performance status ≤ 2 * For Phase I: Pre-chemotherapy platelet count ≤ 300 Gi/L in the screening period before the subject start their first planned cycle of treatment with gemcitabine monotherapy OR gemcitabine in combination with carboplatin or cisplatin in the study. * For Phase II (Part 1 and 2): Subjects must meet one of the following platelet count entry criteria: 1. Subjects have not started the first cycle in this disease setting and have a platelet count \< 150 Gi/L in the screening period as measured within 3 days before Day -5, OR 2. Subjects started chemotherapy for this disease setting and had platelet count \< 150 Gi/L on Day 1 in the preceding cycle before entry into the study, OR 3. Platelet count \< 100 Gi/L at Day 8 in the preceding cycle before entry into the study, OR 4. Platelet count \< 100 Gi/L at Day 15 in the preceding cycle before entry into the study (for subjects receiving Gemcitabine monotherapy) Note: For any of these platelet counts, a repeated platelet count may be allowed only once to ensure that the subject meets the above platelet count criteria and the latest count will be taken for the assessment of eligibility to the study.. * Subjects with previous chemotherapy treatment in a previous disease setting are allowed provided they have recovered from chemotherapy related toxicity except alopecia (and the lab parameters mentioned in Inclusion criteria in #9). * Adequate organ function during screening period defined by the criteria below (adequate baseline organ function): * SYSTEM LABORATORY VALUES * Hematologic * Platelets, see Inclusion criteria * ANC (absolute neutrophil count) ≥1.5 × 109/L * Hemoglobin ≥9 g/dL * Prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) Within 80 to 120% of the normal range * Hepatic * Albumin ≥2.5 g/dL * Serum bilirubin ≤1.5 x ULN AST and ALT * 3 × ULN without liver metastases * 5 × ULN if documented liver metastases * Renal * Serum Creatinine ≤ 1.2 x ULN * Subjects with AST, ALT or bilirubin values outside the range(s) in the table due to Gilbert's syndrome or asymptomatic gall stones are not excluded. * Women of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to randomization and agree to use effective contraception, during the study and for 4 weeks following the last dose of investigational product. * Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from 2 weeks prior to randomization until 13 weeks after the last dose of study treatment. * Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.

Exclusion criteria

Subjects meeting any of the following criteria must not be enrolled in the study: * Lactating females. * Pre-existing cardiovascular disease (congestive heart failure, New York Heart Association \[NYHA\] Grade III/IV), or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation), unstable angina, or subjects with a QTc \>450 msec (QTc \>480 msec for subjects with Bundle Branch Block) at study entry, or myocardial infarction within the preceding 6 months. Subjects with a34 pacemaker or defibrillator are not excluded provided that their cardiac function is within normal ranges. * Note: For patients with pre-existing NYHA Grade II cardiovascular disease, the investigator should consult with GSK medical monitor before enrolling the subject into the study. * Patients with known factor V leiden, antiphospholipid antibody syndrome, prothrombin gene mutations, ATIII deficiency, protein C deficiency, protein S deficiency OR recent history of arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism) within the preceding 6 months. * Note: for patients with known risk factors for thromboembolism e.g., diabetes, hypercholesterolemia, recent major surgery etc., the investigator should consult with GSK medical monitor before enrolling the patient into the study and all risk factors should be documented in the CRF. * Prior surgery within two weeks before study randomization or radiotherapy (RT) within four weeks before study randomization. Subjects with prior surgery or RT are not permitted into the study unless they have completely recovered from surgery and/or acute RT toxicity except for alopecia. * Note: Note: patients with minor surgeries or outpatient procedures (e.g. insertion of central venous catheter) are immediately allowed in the study provided that there were no complications from the procedure or surgery. * History of prior radiotherapy to more than 20% bone marrow bearing sites. * History of platelet agglutination abnormality, platelet disorders or dysfunction or bleeding disorder that prevents reliable measurement of platelet counts. * Subjects with a history of CNS metastases or clinical signs or symptoms of brain and/or leptomeningeal metastases confirmed by CT or MRI brain scan unless properly treated. Subjects with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to randomization will be excluded. * Treated brain metastases are defined * Having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. * Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Note: if subject has performed a CT scan immediately prior to the screening period and CT could not be repeated, an MRI should be performed in the screening period to exclude the development of brain metastases and/or the progression of the pre-existing brain metastatic lesion(s). * Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of investigational product in the study. Concurrent participation in another interventional clinical trial or administration of any investigational drug during the study is also not permitted. * A known immediate or delayed hypersensitivity reaction or idiosyncrasy that, in the opinion of the Investigator or GSK Medical Monitor is due to drugs chemically related to eltrombopag or excipients (e.g. mannitol). * Subjects with known Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV). Subjects with Gilbert's Syndrome are permitted into the study.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	From Cycle 1, Day 1 (C1D1) until at least 30 days post-investigational product discontinuation (longer for AEs considered related to study participation)	AEs are coded using the standard Medical Dictionary for Regulatory Activities (MedDRA) and were graded by the investigator according to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), version 4.0. AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.
Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	After Baseline (C1D1), on-treatment and 30 day follow-up	Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), lymphocytes (decreased), total absolute neutrophil count (ANC), platelets (PLT) and white blood cells (WBC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participant available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	After Baseline (C1D1), on-treatment and 30 day follow-up	Clinical chemistry laboratory parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Clinical chemistry laboratory parameters included albumin (Alb), urea/blood urea nitrogen (BUN), creatinine, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), total bilirubin (TB), direct bilirubin (DB) and international normalized ratio/Prothrombin time (PT). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I	After Baseline (C1D1), on-treatment and 30 day follow-up	The number of participants with at least 1 change from Baseline in creatinine, with an increase \>=26.5 UMOL/L are reported. Creatinine clearance is estimated using the Cockcroft-Gault formula which is a method to approximate kidney function. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1.
Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, C1D1, C2D1, C2D8, C2D15, C3D1, C4D1, C4D22, C5D1, C5D8, C6D1, C6D15	ECOG-Zubrod scores for the performance status are defined as follows: Score 0: Fully active, 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: ambulatory and capable of all self-care but unable to carry out any work activities, 3: capable of only limited self-care, 4: completely disabled, 5: dead. The data is presented for the participants with the ECOG performance score at the indicated time points during the study.
Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I	C2D4, C2D8, C5D8, C6D15	A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and post-dose on C2D4. Three further ECGs were carried out at C2D8, C5D8 and C6D15. Change in ECG findings were categorized as 'Clinically significant change: favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Any time post-Baseline is defined by counting the participants under the worst result experienced post-Baseline. The best to worst order is 'Clinically significant change: favorable', 'No change or insignificant change', and then 'Clinically significant change (CSC): unfavorable. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II	Day 1 (averaged across cycles 1 to 6)	Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each participant across Cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), Baseline loge(platelet count) and part of study (part 1 or 2 of phase II). Only those participants available at indicated time points were analyzed (represented by n=X,X).

Secondary

Measure	Time frame	Description
Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1 to Cycle 6	Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	Cycle 1 to Cycle 6	Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. Time to recovery (TR) (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22, and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I	All time on chemotherapy treatment	Any delay in a scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants.
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	From first dose of investigational product (IP) until 30 days after discontinuation of IP (Longer for AEs related to study participation)	AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.
Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Screening, Day -5, Day 1 and 8 of Cycles 1 to 6 of 21-day cycle schedule, Day 1, 8 and 15 of cycles 1 to 6 of 28-day schedule, treatment withdrawal and 30-day follow-up	The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were further classified into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline is defined as the Day 1 assessment or the latest possible screening assessment. Across Cycles 1-6 included all assessments after first dose of chemotherapy up to the end of Cycle 6. Data exclused for participants taking drugs that affect platelet function or anticoagulants, from the time that the medication was started.
Number of Participants Requiring a Platelet Transfusion in Phase II	Screening, Day -5, throughout cycles 1 to 6 and up to 30 days after IP discontinuation	Platelet transfusion was used as a rescue medication for the treatment of thrombocytopenia. Number of participants requiring a platelet transfusion during Cycles 1-6 was summarized and compared between treatment groups using a logistic regression model adjusted for cycle duration. Each cycle included assessments starting at Day 1 of the cycle.
Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Cycle 1 to Cycle 6	Any delay in scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants. Number of participants with any delay in dose during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only those participants who actually received chemotherapy are included for the cisplatin and carboplatin components and all participants are included for the gemcitabine components (represented by n=X,X in the category titles).
Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Cycle 1 to Cycle 6	Dose reductions are required following potential drug-related toxicities. Number of participants with any dose reduction during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only participants who actually received chemotherapy were included for the cisplatin and carboplatin components. All participants were included for the gemcitabine components.
Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 1 to Cycle 6	Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on eCRF. The average chemotherapy dose intensity at Day 1 across Cycles 1 to 6, Day 8 across Cycles 1 to 6 and Day 15 across Cycles 1 to 6 was summarized and compared between treatment groups using an ANCOVA model adjusted for cycle duration and part of the study.
Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	After baseline (C1D1), on-treatment and 30 day follow-up	Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included Hemoglobin (Hb) increased, Anemia, Lymphocyte count (Lym), platelet count, White Blood Cell count (WBC) and Total Absolute Neutrophil Count (Total ANC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. participants with missing Baseline value were assumed to have normal Baseline value. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up	Clinical chemistry laboratory parameters with a related CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Worst-case grade change of the laboratory parameters at anytime post-Baseline is presented as Any grade increase, Increase to Grade 3 or Grade 4. Clinical chemistry laboratory parameters included Albumin (Al), creatinine, AST, ALT, ALP, TB, Calcium hypercalcemia (CaHy)/hypocalcemia (CaHo), Glucose hyperglycemia (GluHy)/hypoglycemia (GluHo), Potassium hypernatremia (KHy)/hyponatremia (KHo) and Sodium hypernatremia (NaHy)/hyponatremia (NaHo). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1,C4D8, C4D15, C5D1,C5D8, C5D15, C6D1,C6D8 and C6D15	Pre-chemotherapy platelet count is defined for Cycle 1 as the platelet count (from central laboratory data) immediately preceding the first dose of chemotherapy within Cycle 1. For all subsequent cycles it is defined as the platelet count (from central laboratory data) immediately preceding, but limited to within 2 days prior to the first dose of chemotherapy at Day 1. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at the following time points: Group A; Days 1 and 8 of Cycles 1 to 6. Group B; Days 1, 8 and 15 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	Screening, C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1 and C17D1	ECOG-Zubrod scores for the Performance Status were defined as follows: 0: Fully active, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: Ambulatory and capable of all self-care but unable to carry out any work activities, 3: Capable of only limited self-care, 4: Completely disabled, 5 and Unknown: Dead. The data is presented for the participants with the ECOG performance score at different time points during the study. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II	C1D4	A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and 2 to 6 hours post-dose on C1D4. Change in ECG findings were categorized as 'Clinically significant change (CSC): favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of investigational product. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II	Day 8 (averaged across cycles 1 to 6)	Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 8 scheduled platelet count.
Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II	Day 15 (averaged across cycles 1 to 6)	Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 15 scheduled platelet count.
Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II	Day 1, Day 8, Day 15 (all averaged across cycles 1 to 6)	Within-subject platelet count for each par. was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the par. had data. The average within a treatment group was calculated by summing up the values from each par. within the treatment 21-day cycle dividing it by the number of par. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 1 to 6 are summarized. Blood samples were collected on Day 1 and 8 of Cycles 1 to 6 for 21-day cycle and on Day 1, 8 and 15 from Cycles 1 to 6 for 28-day cycle to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).
Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 1 to Cycle 6	Platelet nadir is defined as the lowest platelet count reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Day 1, Day 4, Day 8, Day 15 and Day 17 of Cycles 1 to 6. 28-day cycle; Day 1, Day 4, Day 8, Day 15, Day 22, Day 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).
Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II	All assessments from Cycle 1 Day 1 to last assessment in Cycle 6	The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 1 to 6. Blood samples were collected to estimate platelet count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.
Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	Cycle 1 to Cycle 6	As per the CTCAE version 4.0, participants with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; participants with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; participants with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and participants with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Participants experiencing thrombocytopenia(Platelets \<150Gi/L) at least once within cycle are presented in the category title as n=X,X.
Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II	Cycle 1 to Cycle 6	Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for 21-day cycle was 21 days and for 28-day cycle was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.
Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 1 to Cycle 6	Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).
Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 1 to Cycle 6	Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. TR (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. Blood samples were collected to estimate platelet count at: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22, and 24of Cycles 1 to 6. Time to recover censored if platelet count did not return to \>=100/150 Gi/L. Censored results are excluded from calculation of summary statistics. Only those participants available at indicated time points were analyzed (represented by n=X, X).
Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II	After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up	Number of participants with at least 1 assessment of change from Baseline in creatinine, with increase \>=26.5 UMOL/L are presented. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of IP.
Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Day 1 (averaged across Cycles 2 to 6), Day 8 (averaged across Cycles 2 to 6)	Within-subject platelet count for each participant was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the participant had data. The average within a treatment group was calculated by summing up the values from each participant within the treatment group and dividing it by the number of participants. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 2 to 6 are summarized. Blood samples were collected on Days 1 and 8 of Cycles 2 to 6 for Group A and on Days 1, 8 and 15 from Cycles 2 to 6 for Group B to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).
Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1 to Cycle 6	Platelet nadir is defined as the lowest platelet count (from central laboratory data) reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 and 2, at Days 1, 4, 8, 15 and 17 of Cycle 3 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).
Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I	All assessments from Cycle 2 Day 1 to last assessment in Cycle 6	The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 2 to 6. For 21-Day Cycle, the chemotherapy cycle consisted of 21 days and for 28-Day Cycle, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-Day Cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-Day Cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.
Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Cycle 1 to Cycle 6	Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: Cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within Cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on electronic case report form (eCRF).
Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Cycle 1 to Cycle 6	As per the CTCAE version 4.0, par. with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; par. with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; par. with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and par. with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Par. experiencing thrombocytopenia (Platelets \<150Gi/L) at least once within a cycle are presented in the category title as n=X,X,X,X.
Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts	Cycle 2 to Cycle 6	Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for Group A was 21 days and for Group B was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.

Countries

Belgium, Canada, Czechia, Finland, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Poland, United States

Participant flow

Recruitment details

Participants (par.) with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin were eligible for enrollment into the study. The study comprised of 2 phases (I & II), with eligible par. being randomized to receive placebo or eltrombopag in each phase.

Pre-assignment details

A total of 108 par. were randomized, of which 101 par. received at least 1 dose of study drug. A maximum of 6 cycles (with some exceptions) of chemotherapy with eltrombopag/placebo were allowed in each phase (either 21-day or 28-day cycle) followed by the 30 day Follow-up visit.

Participants by arm

Arm	Count
Phase I: 21-Day Cycle Placebo Participants receiving gemcitabine on Day 1 and Day 8 plus carboplatin (G+Cb) or cisplatin (G+Cis) on Day 1 (Cis may be divided on Day 1 and Day 8) as a part of the 21-day chemotherapy cycle were administered placebo once daily for 5 days before and 5 days after Day 1 of Cycle 2 and subsequent chemotherapy cycles.	3
Phase I: 21-Day Cycle Eltrombopag 100 mg Participants receiving gemcitabine on Day 1 and Day 8 plus carboplatin (G+Cb) or cisplatin (G+Cis) on Day 1 (Cis may be divided on Day 1 and Day 8) as a part of the 21-day chemotherapy cycle were administered eltrombopag 100 milligrams (mg) once daily for 5 days before and 5 days after Day 1 of Cycle 2 and subsequent chemotherapy cycles.	9
Phase I: 28-Day Cycle Placebo Participants receiving gemcitabine on Day 1, Day 8 and Day 15 as a part of 28-day chemotherapy cycle, were administered placebo once daily for 5 days before and 5 days after Day 1 of Cycle 2 and subsequent chemotherapy cycles.	4
Phase I: 28-Day Cycle Eltrombopag 100 mg Participants receiving gemcitabine on Day 1, Day 8 and Day 15 as a part of 28-day chemotherapy cycle, were administered eltrombopag 100 mg once daily for 5 days before and 5 days after Day 1 of Cycle 2 and subsequent chemotherapy cycles.	10
Phase II: Placebo Participants receiving gemcitabine plus carboplatin or cisplatin as a part of 21-day chemotherapy cycle or gemcitabine alone as a part of 28-day chemotherapy cycle, were administered placebo once daily for 5 days before and 5 days after Day 1 of each chemotherapy cycle (up to a maximum of 6 cycles).	23
Phase II: Eltrombopag 100 mg Participants receiving gemcitabine plus carboplatin or cisplatin as a part of 21-day chemotherapy cycle or gemcitabine alone as a part of 28-day chemotherapy cycle were administered eltrombopag 100 mg once daily for 5 days before and 5 days after Day 1 of each chemotherapy cycle (up to a maximum of 6 cycles).	52
Total	101

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005
Phase I (168 Days)	Adverse Event	0	0	0	1	0	0
Phase I (168 Days)	Lost to Follow-up	1	0	0	1	0	0
Phase I (168 Days)	Physician Decision	0	1	2	0	0	0
Phase I (168 Days)	Withdrawal by Subject	0	0	0	3	0	0
Phase II (168 Days)	Adverse Event	0	0	0	0	3	6
Phase II (168 Days)	Ongoing	0	0	0	0	1	0
Phase II (168 Days)	Physician Decision	0	0	0	0	5	11
Phase II (168 Days)	Protocol Violation	0	0	0	0	0	1
Phase II (168 Days)	Withdrawal by Subject	0	0	0	0	7	15

Baseline characteristics

Characteristic	Phase I: 21-Day Cycle Placebo	Phase I: 21-Day Cycle Eltrombopag 100 mg	Phase I: 28-Day Cycle Placebo	Phase I: 28-Day Cycle Eltrombopag 100 mg	Phase II: Placebo	Phase II: Eltrombopag 100 mg	Total
Age, Continuous	53.3 Years STANDARD_DEVIATION 3.79	53.8 Years STANDARD_DEVIATION 11.27	61.8 Years STANDARD_DEVIATION 22.82	65.6 Years STANDARD_DEVIATION 8.41	64.4 Years STANDARD_DEVIATION 9.96	66.3 Years STANDARD_DEVIATION 8.98	64.1 Years STANDARD_DEVIATION 10.56
Race/Ethnicity, Customized African American/African Heritage	1 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	3 Participants
Race/Ethnicity, Customized Central/South Asian Heritage	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Japanese/East Asian Heritage/South East Asian	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	2 Participants
Race/Ethnicity, Customized White	2 Participants	8 Participants	3 Participants	8 Participants	22 Participants	52 Participants	95 Participants
Sex: Female, Male Female	1 Participants	7 Participants	3 Participants	3 Participants	13 Participants	23 Participants	50 Participants
Sex: Female, Male Male	2 Participants	2 Participants	1 Participants	7 Participants	10 Participants	29 Participants	51 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	3 / 3	9 / 9	4 / 4	10 / 10	22 / 23	47 / 52
serious Total, serious adverse events	1 / 3	5 / 9	1 / 4	2 / 10	13 / 23	17 / 52

Outcome results

Primary

Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II

Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each participant across Cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), Baseline loge(platelet count) and part of study (part 1 or 2 of phase II). Only those participants available at indicated time points were analyzed (represented by n=X,X).

Time frame: Day 1 (averaged across cycles 1 to 6)

Population: Intent-to Treat (ITT) Population: all randomized participants.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
21-Day Cycle Placebo	Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II	193.34 Giga (10^9) cells per liter (Gi/L)	Geometric Coefficient of Variation 54.5
21-Day Cycle Eltrombopag 100 mg	Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II	246.20 Giga (10^9) cells per liter (Gi/L)	Geometric Coefficient of Variation 49.8

p-value: 0.10395% CI: [-3.9, 52.5]ANCOVA

Primary

Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I

The number of participants with at least 1 change from Baseline in creatinine, with an increase \>=26.5 UMOL/L are reported. Creatinine clearance is estimated using the Cockcroft-Gault formula which is a method to approximate kidney function. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1.

Time frame: After Baseline (C1D1), on-treatment and 30 day follow-up

Population: Safety Population

Arm	Measure	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I	3 Participants
28-Day Cycle Placebo	Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I	2 Participants

Primary

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I

AEs are coded using the standard Medical Dictionary for Regulatory Activities (MedDRA) and were graded by the investigator according to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), version 4.0. AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.

Time frame: From Cycle 1, Day 1 (C1D1) until at least 30 days post-investigational product discontinuation (longer for AEs considered related to study participation)

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Renal AEs On-therapy+30 days	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Liver AEs On-therapy+30 days	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE Post-therapy	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Platelet count increased On-therapy+30 days	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	>=Grade 3 AEs On-therapy+30 days	2 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Treatment-related AEs On-therapy+30 days	2 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Leukopenia On-therapy+30 days	1 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thrombocytopenia On-therapy+30 days	2 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE On-therapy+30 days	3 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE Pre-therapy	3 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Anemia On-therapy+30 days	1 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Neutropenia On-therapy+30 days	3 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE On-therapy+30 days	1 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thrombocytosis On-therapy+30 days	2 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Cardiac AEs On-therapy+30 days	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thromboembolic events On-therapy+30 days	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE Post-therapy	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE Pre-therapy	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE On-therapy+30 days	9 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE Pre-therapy	8 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE Pre-therapy	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE On-therapy+30 days	5 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE Post-therapy	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE Post-therapy	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Treatment-related AEs On-therapy+30 days	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	>=Grade 3 AEs On-therapy+30 days	7 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Liver AEs On-therapy+30 days	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Renal AEs On-therapy+30 days	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thromboembolic events On-therapy+30 days	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Cardiac AEs On-therapy+30 days	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Neutropenia On-therapy+30 days	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Anemia On-therapy+30 days	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thrombocytopenia On-therapy+30 days	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Leukopenia On-therapy+30 days	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thrombocytosis On-therapy+30 days	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Platelet count increased On-therapy+30 days	0 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE Post-therapy	0 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Renal AEs On-therapy+30 days	2 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thromboembolic events On-therapy+30 days	0 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE On-therapy+30 days	1 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Platelet count increased On-therapy+30 days	0 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Cardiac AEs On-therapy+30 days	1 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thrombocytosis On-therapy+30 days	1 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Neutropenia On-therapy+30 days	2 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE On-therapy+30 days	3 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Anemia On-therapy+30 days	1 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE Pre-therapy	4 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thrombocytopenia On-therapy+30 days	3 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE Pre-therapy	0 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Treatment-related AEs On-therapy+30 days	1 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE Post-therapy	0 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	>=Grade 3 AEs On-therapy+30 days	2 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Leukopenia On-therapy+30 days	2 Participants
28-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Liver AEs On-therapy+30 days	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Treatment-related AEs On-therapy+30 days	6 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Leukopenia On-therapy+30 days	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Anemia On-therapy+30 days	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Renal AEs On-therapy+30 days	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE On-therapy+30 days	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE Pre-therapy	9 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE Pre-therapy	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thromboembolic events On-therapy+30 days	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE Post-therapy	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Platelet count increased On-therapy+30 days	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thrombocytopenia On-therapy+30 days	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Cardiac AEs On-therapy+30 days	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any AE On-therapy+30 days	10 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Any SAE Post-therapy	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Liver AEs On-therapy+30 days	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Neutropenia On-therapy+30 days	5 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	>=Grade 3 AEs On-therapy+30 days	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I	Thrombocytosis On-therapy+30 days	2 Participants

Primary

Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I

A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and post-dose on C2D4. Three further ECGs were carried out at C2D8, C5D8 and C6D15. Change in ECG findings were categorized as 'Clinically significant change: favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Any time post-Baseline is defined by counting the participants under the worst result experienced post-Baseline. The best to worst order is 'Clinically significant change: favorable', 'No change or insignificant change', and then 'Clinically significant change (CSC): unfavorable. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

Time frame: C2D4, C2D8, C5D8, C6D15

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I	No change or insignificant change n=3,9,3,8	3 Participants
21-Day Cycle Placebo	Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I	CSC: unfavorable, n=3,9,3,8	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I	CSC: unfavorable, n=3,9,3,8	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I	No change or insignificant change n=3,9,3,8	8 Participants
28-Day Cycle Placebo	Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I	No change or insignificant change n=3,9,3,8	3 Participants
28-Day Cycle Placebo	Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I	CSC: unfavorable, n=3,9,3,8	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I	No change or insignificant change n=3,9,3,8	7 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I	CSC: unfavorable, n=3,9,3,8	1 Participants

Primary

Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I

Clinical chemistry laboratory parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Clinical chemistry laboratory parameters included albumin (Alb), urea/blood urea nitrogen (BUN), creatinine, aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), total bilirubin (TB), direct bilirubin (DB) and international normalized ratio/Prothrombin time (PT). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

Time frame: After Baseline (C1D1), on-treatment and 30 day follow-up

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 0, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 0, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 0, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 0, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 0, n=3,9,4,10	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 0, n=3,9,4,10	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 0, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 0, n=3,9,4,10	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 0, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 2, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 0, n=3,9,4,10	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 0, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 1, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 0, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 0, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 0, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 0, n=3,9,4,10	7 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 1, n=3,9,4,10	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 0, n=3,9,4,10	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 1, n=3,9,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 2, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 0, n=3,9,4,10	5 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 0, n=3,9,4,10	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 0, n=3,9,4,10	8 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 0, n=3,9,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 0, n=3,9,4,10	8 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 0, n=3,9,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 0, n=3,9,4,10	5 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 2, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 1, n=3,9,4,10	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 3, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 3, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 2, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 0, n=3,9,4,10	8 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 1, n=3,9,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 1, n=3,9,4,10	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 2, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 1, n=3,9,4,10	5 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 1, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 3, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 0, n=3,9,4,10	7 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 0, n=3,9,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 0, n=3,9,4,10	9 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 2, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 2, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 2, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 0, n=3,9,4,10	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 2, n=3,9,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 1, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 2, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 0, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 0, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 0, n=3,9,4,10	4 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 3, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 1, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 0, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 0, n=3,9,4,10	4 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 1, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 0, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 1, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 0, n=3,9,4,10	4 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 0, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 0, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 0, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 1, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 3, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 0, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 1, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 0, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 1, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 0, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 0, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 1, n=3,9,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 1, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 0, n=3,9,4,10	9 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 1, n=3,9,4,10	5 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 0, n=3,9,4,10	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 0, n=3,9,4,10	10 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 0, n=3,9,4,10	5 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 1, n=3,9,4,10	5 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 1, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Alb, Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 0, n=3,9,4,10	5 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypocalcemia), Grade 0, n=3,9,4,10	9 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 0, n=3,9,4,10	7 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 0, n=3,9,4,10	6 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 1, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 3, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 2, n=3,9,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 0, n=3,9,4,10	8 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALP, Grade 3, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 0, n=3,9,4,10	8 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 2, n=3,9,4,10	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 1, n=3,9,4,10	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Ca (hypercalcemia), Grade 0, n=3,9,4,10	10 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 1, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 1, n=3,9,4,10	5 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hyperglycemia), Grade 0, n=3,9,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	AST, Grade 3, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	ALT, Grade 0, n=3,9,4,10	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Glu (hypoglycemia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hyponatremia), Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Na (hypernatremia), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	TB, Grade 3, n=3,9,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 0, n=3,9,4,10	9 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	Creatinine, Grade 1, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hypokalemia), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I	K (hyperkalemia), Grade 1, n=3,9,4,10	0 Participants

Primary

Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I

Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), lymphocytes (decreased), total absolute neutrophil count (ANC), platelets (PLT) and white blood cells (WBC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those participant available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

Time frame: After Baseline (C1D1), on-treatment and 30 day follow-up

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Increased), Grade 0, n=3,9,4,10	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 4, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Total ANC, Grade 1, n=1,2,1,2	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 3, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 0, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 3, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 1, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 3, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Increased), Grade 0, n=3,9,4,10	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Increased), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 2, n=3,9,4,10	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 0, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 4, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 2, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 3, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 0, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 4, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Total ANC, Grade 0, n=1,2,1,2	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 0, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 3, n=3,9,4,10	5 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 0, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Total ANC, Grade 1, n=1,2,1,2	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 3, n=3,9,4,10	5 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 3, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 0, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 3, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 4, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 1, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 4, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 2, n=3,9,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Total ANC, Grade 0, n=1,2,1,2	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 4, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 2, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Increased), Grade 0, n=3,9,4,10	8 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 1, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 2, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 2, n=3,9,4,10	6 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Increased), Grade 2, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Increased), Grade 0, n=3,9,4,10	9 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Total ANC, Grade 0, n=1,2,1,2	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Increased), Grade 0, n=3,9,4,10	4 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 2, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 3, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Increased), Grade 0, n=3,9,4,10	4 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Increased), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 0, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 3, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 4, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Total ANC, Grade 1, n=1,2,1,2	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 0, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 1, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 3, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 4, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 0, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 3, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 4, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 4, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 4, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 4, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 3, n=3,9,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 2, n=3,9,4,10	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 3, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 0, n=3,9,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 1, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Decreased), Grade 0, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 1, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 1, n=3,9,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Increased), Grade 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Lymphocytes (Increased), Grade 0, n=3,9,4,10	10 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Increased), Grade 0, n=3,9,4,10	10 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	WBC, Grade 2, n=3,9,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 1, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 3, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 2, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 0, n=3,9,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Total ANC, Grade 1, n=1,2,1,2	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Hemoglobin (Anemia), Grade 2, n=3,9,4,10	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	PLT, Grade 3, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I	Total ANC, Grade 0, n=1,2,1,2	0 Participants

Primary

Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I

ECOG-Zubrod scores for the performance status are defined as follows: Score 0: Fully active, 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: ambulatory and capable of all self-care but unable to carry out any work activities, 3: capable of only limited self-care, 4: completely disabled, 5: dead. The data is presented for the participants with the ECOG performance score at the indicated time points during the study.

Time frame: Screening, C1D1, C2D1, C2D8, C2D15, C3D1, C4D1, C4D22, C5D1, C5D8, C6D1, C6D15

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 0, n=1,1,1,4	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 0, n=1,0,1,0	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 0, n=0,1,0,0	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 2, n=0,0,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 1, n=1,0,1,0	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 0, n=2,6,1,7	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 2, n=0,0,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 3, n=2,6,1,7	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 2, n=1,0,1,0	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 3, n=0,0,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 0, n=0,0,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 1, n=1,1,1,4	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 3, n=1,0,1,0	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 1, n=0,0,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 0, n=3,9,4,10	3 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 0, n=0,1,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 0, n=1,3,1,4	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 0, n=0,0,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 0, n=3,9,4,10	3 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 1, n=0,1,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 2, n=2,6,1,7	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 2, n=3,8,4,10	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 3, n=0,1,0,0	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 2, n=0,1,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 1, n=1,3,1,4	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 2, n=1,1,1,4	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 3, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 3, n=0,1,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 3, n=0,0,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 1, n=3,8,4,10	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 0, n=2,6,2,7	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 0, n=3,8,4,10	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 2, n=1,3,1,4	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 1, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 1, n=2,6,2,7	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 1, n=0,0,0,1	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 3, n=1,1,1,4	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 2, n=2,6,2,7	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 1, n=2,6,1,7	1 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 3, n=1,3,1,4	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 2, n=0,1,0,0	NA Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 3, n=2,6,2,7	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 3, n=3,8,4,10	0 Participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 1, n=0,1,0,0	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 2, n=0,1,0,0	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 0, n=2,6,1,7	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 1, n=2,6,1,7	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 0, n=0,0,0,1	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 2, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 2, n=2,6,1,7	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 1, n=3,8,4,10	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 3, n=2,6,1,7	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 1, n=0,0,0,1	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 0, n=0,0,0,1	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 1, n=0,0,0,1	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 3, n=0,0,0,1	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 2, n=0,0,0,1	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 3, n=0,0,0,1	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 2, n=0,0,0,1	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 3, n=0,1,0,0	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 0, n=1,3,1,4	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 3, n=3,8,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 0, n=3,9,4,10	5 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 1, n=1,3,1,4	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 2, n=1,3,1,4	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 0, n=3,8,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 3, n=1,3,1,4	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 0, n=1,0,1,0	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 0, n=1,1,1,4	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 1, n=1,0,1,0	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 1, n=0,1,0,0	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 3, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 2, n=1,0,1,0	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 2, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 3, n=1,0,1,0	NA Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 1, n=1,1,1,4	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 0, n=0,1,0,1	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 0, n=0,1,0,0	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 1, n=0,1,0,1	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 0, n=3,9,4,10	5 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 2, n=0,1,0,1	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 2, n=1,1,1,4	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 3, n=0,1,0,1	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 0, n=2,6,2,7	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 2, n=3,8,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 1, n=2,6,2,7	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 1, n=3,9,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 2, n=2,6,2,7	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 3, n=1,1,1,4	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 3, n=2,6,2,7	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 1, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 3, n=1,3,1,4	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 0, n=0,1,0,0	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 1, n=0,1,0,0	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 2, n=0,1,0,0	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 3, n=0,1,0,0	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 1, n=3,8,4,10	1 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 0, n=1,1,1,4	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 1, n=1,1,1,4	1 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 2, n=1,1,1,4	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 3, n=1,1,1,4	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 2, n=3,8,4,10	1 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 0, n=0,0,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 1, n=0,0,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 2, n=0,0,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 3, n=0,0,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 3, n=3,8,4,10	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 0, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 0, n=1,0,1,0	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 1, n=1,0,1,0	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 2, n=1,0,1,0	1 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 3, n=1,0,1,0	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 0, n=0,1,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 1, n=0,1,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 2, n=0,1,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 0, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 3, n=0,1,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 0, n=2,6,2,7	2 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 1, n=2,6,2,7	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 2, n=2,6,2,7	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 1, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 3, n=2,6,2,7	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 0, n=2,6,1,7	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 1, n=2,6,1,7	1 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 2, n=2,6,1,7	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 2, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 3, n=2,6,1,7	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 1, n=3,9,4,10	3 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 0, n=0,0,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 1, n=0,0,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 2, n=0,0,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 3, n=0,0,0,1	NA Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 3, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 0, n=1,3,1,4	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 1, n=1,3,1,4	1 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 2, n=1,3,1,4	0 Participants
28-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 0, n=3,8,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 1, n=0,0,0,1	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 0, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 1, n=3,9,4,10	7 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	Screening, Score 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 0, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 1, n=3,9,4,10	7 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 2, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C1D1, Score 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 0, n=3,8,4,10	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 1, n=3,8,4,10	8 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 2, n=3,8,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D1, Score 3, n=3,8,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 0, n=1,0,1,0	NA Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 1, n=1,0,1,0	NA Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 2, n=1,0,1,0	NA Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D8, Score 3, n=1,0,1,0	NA Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 0, n=0,1,0,1	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 1, n=0,1,0,1	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 2, n=0,1,0,1	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C2D15, Score 3, n=0,1,0,1	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 0, n=2,6,2,7	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 1, n=2,6,2,7	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 2, n=2,6,2,7	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C3D1, Score 3, n=2,6,2,7	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 0, n=2,6,1,7	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 1, n=2,6,1,7	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 2, n=2,6,1,7	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D1, Score 3, n=2,6,1,7	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 0, n=0,0,0,1	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 2, n=0,0,0,1	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C4D22, Score 3, n=0,0,0,1	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 0, n=1,3,1,4	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 1, n=1,3,1,4	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 2, n=1,3,1,4	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D1, Score 3, n=1,3,1,4	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 0, n=0,1,0,0	NA Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 1, n=0,1,0,0	NA Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 2, n=0,1,0,0	NA Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C5D8, Score 3, n=0,1,0,0	NA Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 0, n=1,1,1,4	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 1, n=1,1,1,4	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 2, n=1,1,1,4	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D1, Score 3, n=1,1,1,4	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 0, n=0,0,0,1	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 1, n=0,0,0,1	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 2, n=0,0,0,1	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I	C6D15, Score 3, n=0,0,0,1	0 Participants

Secondary

Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II

The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 1 to 6. Blood samples were collected to estimate platelet count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.

Time frame: All assessments from Cycle 1 Day 1 to last assessment in Cycle 6

Population: ITT Population:Participants with platelet count data in at least one cycle in the study.

Arm	Measure	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II	153.00 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 96.079
21-Day Cycle Eltrombopag 100 mg	Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II	189.48 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 79.583

Secondary

Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I

Pre-chemotherapy platelet count is defined for Cycle 1 as the platelet count (from central laboratory data) immediately preceding the first dose of chemotherapy within Cycle 1. For all subsequent cycles it is defined as the platelet count (from central laboratory data) immediately preceding, but limited to within 2 days prior to the first dose of chemotherapy at Day 1. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at the following time points: Group A; Days 1 and 8 of Cycles 1 to 6. Group B; Days 1, 8 and 15 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

Time frame: C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1,C4D8, C4D15, C5D1,C5D8, C5D15, C6D1,C6D8 and C6D15

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D1, n=1,6,1,6	298.0 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D15, n=0,0,2,5	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D15, n=0,0,2,6	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D15, n=0,0,1,2	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D8, n=2,6,2,5	285.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 39.6
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D1, n=2,5,2,7	464.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 36.77
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D1, n=1,1,1,3	512.0 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D15, n=0,0,1,4	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D15, n=0,0,2, 6	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D1, n=3,9,4,9	239.3 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 75.87
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D8, n=1,1,1,4	144.0 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D1, n=1,2,1,4	245.0 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D1, n=2,9,4,8	443.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 168.29
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D8, n=1,1,0,3	251.0 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D15, n=0,0,1,6	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D8, n=1,5,1,6	261.0 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D8, n=2,7,3,9	221.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 94.75
21-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D8, n=3,6,3,9	180.7 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 65.03
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D15, n=0,0,2, 6	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D1, n=3,9,4,9	244.8 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 48.47
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D8, n=3,6,3,9	143.8 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 33.88
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D1, n=2,9,4,8	545.8 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 131.66
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D8, n=2,7,3,9	335.6 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 134.06
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D15, n=0,0,2,6	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D1, n=2,5,2,7	484.6 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 188.16
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D8, n=2,6,2,5	292.2 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 161.11
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D15, n=0,0,2,5	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D1, n=1,6,1,6	394.7 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 154.28
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D8, n=1,5,1,6	249.8 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 122.29
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D15, n=0,0,1,6	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D1, n=1,2,1,4	529.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 340.12
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D8, n=1,1,1,4	123.0 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D15, n=0,0,1,4	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D1, n=1,1,1,3	123.0 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D8, n=1,1,0,3	137.0 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D15, n=0,0,1,2	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D8, n=2,7,3,9	163.3 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 35.3
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D1, n=1,6,1,6	609.0 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D8, n=1,5,1,6	335.0 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D1, n=2,9,4,8	284.8 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 84.11
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D15, n=0,0,1,2	113.0 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D15, n=0,0,1,6	86.0 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D8, n=1,1,0,3	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D1, n=1,2,1,4	337.0 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D15, n=0,0,2, 6	135.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 84.85
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D8, n=1,1,1,4	311.0 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D1, n=3,9,4,9	223.8 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 79.96
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D15, n=0,0,1,4	75.0 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D8, n=3,6,3,9	144.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 44.17
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D1, n=2,5,2,7	290.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 180.31
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D15, n=0,0,2,6	80.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 0.71
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D8, n=2,6,2,5	293.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 199.4
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D1, n=1,1,1,3	440.0 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D15, n=0,0,2,5	92.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 45.25
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D1, n=2,5,2,7	435.4 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 145.57
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D1, n=1,1,1,3	360.3 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 133.45
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D8, n=1,1,1,4	403.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 195.31
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D1, n=1,6,1,6	388.3 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 166.07
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D1, n=2,9,4,8	473.3 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 117.07
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D1, n=3,9,4,9	207.7 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 65.51
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D8, n=3,6,3,9	135.6 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 52.52
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D8, n=1,5,1,6	366.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 143.75
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D8, n=2,7,3,9	333.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 146.59
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D15, n=0,0,1,2	101.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 48.08
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D15, n=0,0,1,4	140.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 42.93
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C4 D15, n=0,0,1,6	169.8 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 120.56
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C1 D15, n=0,0,2, 6	97.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 39.15
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C2 D15, n=0,0,2,6	142.7 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 63.14
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D15, n=0,0,2,5	183.4 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 119.12
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C5 D1, n=1,2,1,4	406.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 174.89
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C3 D8, n=2,6,2,5	465.2 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 260.2
28-Day Cycle Eltrombopag 100 mg	Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I	C6 D8, n=1,1,0,3	428.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 210.71

Secondary

Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I

Within-subject platelet count for each participant was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the participant had data. The average within a treatment group was calculated by summing up the values from each participant within the treatment group and dividing it by the number of participants. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 2 to 6 are summarized. Blood samples were collected on Days 1 and 8 of Cycles 2 to 6 for Group A and on Days 1, 8 and 15 from Cycles 2 to 6 for Group B to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X,X,X in the category titles).

Time frame: Day 1 (averaged across Cycles 2 to 6), Day 8 (averaged across Cycles 2 to 6)

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day15, n=0,0,3,10	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cb, Day 1, n=1,3,0,0	296.80 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cis, Day 8, n=2,6,0,0	326.85 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 119.006
21-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cis, Day 1, n=2,6,0,0	322.50 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 82.731
21-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cb, Day 8, n=1,3,0,0	235.00 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day8, n=0,0,4,10	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day1, n=0,0,4,9	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cb, Day 8, n=1,3,0,0	232.10 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 77.329
21-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cb, Day 1, n=1,3,0,0	275.00 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 144.253
21-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day8, n=0,0,4,10	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cis, Day 1, n=2,6,0,0	526.00 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 86.408
21-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day1, n=0,0,4,9	NA Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cis, Day 8, n=2,6,0,0	296.75 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 119.342
21-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day15, n=0,0,3,10	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cb, Day 1, n=1,3,0,0	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cb, Day 8, n=1,3,0,0	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cis, Day 1, n=2,6,0,0	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cis, Day 8, n=2,6,0,0	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day1, n=0,0,4,9	309.20 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 123.133
28-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day8, n=0,0,4,10	204.20 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 80.822
28-Day Cycle Placebo	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day15, n=0,0,3,10	75.37 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 18.292
28-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day1, n=0,0,4,9	442.79 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 114.593
28-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cis, Day 8, n=2,6,0,0	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cb, Day 1, n=1,3,0,0	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day15, n=0,0,3,10	164.24 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 94.905
28-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cis, Day 1, n=2,6,0,0	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	G+Cb, Day 8, n=1,3,0,0	NA Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Eltrombopag 100 mg	Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I	Gm, Day8, n=0,0,4,10	355.09 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 148.539

Secondary

Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I

The average daily area under the platelet-time course was normalized by dividing the area under curve by total duration. This gives an estimated average platelet value over the time period from cycles 2 to 6. For 21-Day Cycle, the chemotherapy cycle consisted of 21 days and for 28-Day Cycle, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-Day Cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-Day Cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6.

Time frame: All assessments from Cycle 2 Day 1 to last assessment in Cycle 6

Population: Safety Population

Arm	Measure	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I	260.97 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 67.581
21-Day Cycle Eltrombopag 100 mg	Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I	307.59 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 95.11
28-Day Cycle Placebo	Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I	183.68 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 55.366
28-Day Cycle Eltrombopag 100 mg	Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I	291.18 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 99.718

Secondary

Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I

Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

Time frame: Cycle 1 to Cycle 6

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1, n=3,9,4,10	15.7 Days	Standard Deviation 0.58
21-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 2, n=2,9,4,10	15.0 Days	Standard Deviation 1.41
21-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 3, n=2,7,2,7	15.0 Days	Standard Deviation 1.41
21-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 4, n=2,6,1,7	14.0 Days	Standard Deviation 0
21-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 5, n=1,2,1,4	15.0 Days	—
21-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 6, n=1,1,1,4	16.0 Days	—
21-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 6, n=1,1,1,4	14.0 Days	—
21-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 4, n=2,6,1,7	13.5 Days	Standard Deviation 3.33
21-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1, n=3,9,4,10	11.4 Days	Standard Deviation 5.53
21-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 3, n=2,7,2,7	12.9 Days	Standard Deviation 3.02
21-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 2, n=2,9,4,10	12.9 Days	Standard Deviation 4.68
21-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 5, n=1,2,1,4	11.5 Days	Standard Deviation 6.36
28-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 2, n=2,9,4,10	14.0 Days	Standard Deviation 5.72
28-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 3, n=2,7,2,7	23.5 Days	Standard Deviation 0.71
28-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 4, n=2,6,1,7	14.0 Days	—
28-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 6, n=1,1,1,4	23.0 Days	—
28-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 5, n=1,2,1,4	14.0 Days	—
28-Day Cycle Placebo	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1, n=3,9,4,10	13.8 Days	Standard Deviation 6.13
28-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 5, n=1,2,1,4	21.5 Days	Standard Deviation 1
28-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 6, n=1,1,1,4	15.5 Days	Standard Deviation 5.2
28-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 2, n=2,9,4,10	19.2 Days	Standard Deviation 4.42
28-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 4, n=2,6,1,7	17.4 Days	Standard Deviation 6.16
28-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1, n=3,9,4,10	13.8 Days	Standard Deviation 4.73
28-Day Cycle Eltrombopag 100 mg	Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I	Cycle 3, n=2,7,2,7	17.6 Days	Standard Deviation 4.5

Secondary

Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II

Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on eCRF. The average chemotherapy dose intensity at Day 1 across Cycles 1 to 6, Day 8 across Cycles 1 to 6 and Day 15 across Cycles 1 to 6 was summarized and compared between treatment groups using an ANCOVA model adjusted for cycle duration and part of the study.

Time frame: Cycle 1 to Cycle 6

Population: ITT Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 6, n=5,7	84.4 Dose Intensity (%)	Standard Deviation 21.92
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 1, n=23,48	96.6 Dose Intensity (%)	Standard Deviation 10.65
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 2, n=19,37	113.1 Dose Intensity (%)	Standard Deviation 33.91
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 3, n=13,26	102.6 Dose Intensity (%)	Standard Deviation 42.2
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 4, n=11,19	96.6 Dose Intensity (%)	Standard Deviation 27.65
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 5, n=6,12	102.2 Dose Intensity (%)	Standard Deviation 31.88
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 1-6, n=23,49	98.5 Dose Intensity (%)	Standard Deviation 18.26
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 6, n=5,7	65.2 Dose Intensity (%)	Standard Deviation 25.48
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 4, n=11,19	90.7 Dose Intensity (%)	Standard Deviation 30
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 1, n=23,48	97.9 Dose Intensity (%)	Standard Deviation 6.19
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 1-6, n=23,49	94.6 Dose Intensity (%)	Standard Deviation 15.71
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 2, n=19,37	97.8 Dose Intensity (%)	Standard Deviation 24.99
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 5, n=6,12	81.3 Dose Intensity (%)	Standard Deviation 25.39
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II	Cycle 3, n=13,26	98.7 Dose Intensity (%)	Standard Deviation 35.77

Secondary

Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I

Dose intensity of chemotherapy is defined as the actual dose of chemotherapy given as a percentage of the scheduled C1D1/C1D8 dose, as applicable, within this study: Cycle Dose Intensity (%) = Total Actual dose (mg/m\^2) within Cycle \*100/ Total Scheduled dose (mg/m\^2) in Cycle 1; wherein Actual Dose (mg/m\^2) = Actual dose (mg)/Body Surface Area reported on electronic case report form (eCRF).

Time frame: Cycle 1 to Cycle 6

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 5, n=1,1,0,0	100.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 4, n=1,4,0,0	100.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 3, n=1,2,0,0	93.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 3, n=1,4,0,0	100.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 6, n=1,1,0,0	99.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 5, n=0,1,0,0	NA Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 2, n=1,5,0,0	100.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 1, n=2,6,0,0	100.0 Dose Intensity (%)	Standard Deviation 0
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 3, n=0,0,1,4	NA Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 1, n=1,2,0,0	99.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 4, n=1,2,0,0	91.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 1, n=2,5,0,0	100.0 Dose Intensity (%)	Standard Deviation 0
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 5, n=0,0,0,3	NA Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 2, n=1,2,0,0	99.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 2, n=1,6,0,0	100.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 2, n=1,3,0,0	100.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 2, n=0,0,1,7	NA Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 3, n=1,2,0,0	99.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 6, n=1,1,0,0	87.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 4, n=1,3,0,0	100.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 4, n=0,0,0,4	NA Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 4, n=1,2,0,0	49.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 3, n=1,5,0,0	100.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 1, n=1,3,0,0	101.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 1, n=0,0,1,7	NA Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 5, n=1,1,0,0	99.0 Dose Intensity (%)	—
21-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 6, n=0,0,0,3	NA Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 5, n=1,1,0,0	74.0 Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 6, n=1,1,0,0	79.0 Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 6, n=1,1,0,0	74.0 Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 1, n=1,3,0,0	88.7 Dose Intensity (%)	Standard Deviation 14.05
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 5, n=1,1,0,0	71.0 Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 2, n=1,3,0,0	103.0 Dose Intensity (%)	Standard Deviation 5.2
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 1, n=2,6,0,0	100.3 Dose Intensity (%)	Standard Deviation 1.03
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 3, n=1,2,0,0	105.0 Dose Intensity (%)	Standard Deviation 5.66
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 4, n=1,2,0,0	107.5 Dose Intensity (%)	Standard Deviation 2.12
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 4, n=0,0,0,4	NA Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 2, n=1,6,0,0	102.8 Dose Intensity (%)	Standard Deviation 6.05
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 1, n=2,5,0,0	99.8 Dose Intensity (%)	Standard Deviation 0.45
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 3, n=1,5,0,0	93.8 Dose Intensity (%)	Standard Deviation 24.34
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 2, n=1,5,0,0	92.8 Dose Intensity (%)	Standard Deviation 24.83
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 4, n=1,4,0,0	100.3 Dose Intensity (%)	Standard Deviation 0.96
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 3, n=0,0,1,4	NA Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 5, n=0,1,0,0	50 Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 3, n=1,4,0,0	104.3 Dose Intensity (%)	Standard Deviation 8.5
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 1, n=1,2,0,0	100.0 Dose Intensity (%)	Standard Deviation 0
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 2, n=0,0,1,7	NA Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 2, n=1,2,0,0	88.5 Dose Intensity (%)	Standard Deviation 17.68
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 5, n=0,0,0,3	NA Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 3, n=1,2,0,0	100.0 Dose Intensity (%)	Standard Deviation 0
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 1, n=0,0,1,7	NA Dose Intensity (%)	—
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 4, n=1,2,0,0	99.5 Dose Intensity (%)	Standard Deviation 0.71
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 4, n=1,3,0,0	83.3 Dose Intensity (%)	Standard Deviation 28.87
21-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 6, n=0,0,0,3	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 3, n=0,0,1,4	100.0 Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 1, n=2,5,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 2, n=1,5,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 3, n=1,4,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 4, n=1,3,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 1, n=2,6,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 2, n=1,6,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 3, n=1,5,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 4, n=1,4,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 5, n=0,1,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 1, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 2, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 3, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 4, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 5, n=1,1,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 6, n=1,1,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 1, n=1,3,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 2, n=1,3,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 3, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 4, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 5, n=1,1,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 6, n=1,1,0,0	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 1, n=0,0,1,7	100.0 Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 2, n=0,0,1,7	100.0 Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 4, n=0,0,0,4	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 5, n=0,0,0,3	NA Dose Intensity (%)	—
28-Day Cycle Placebo	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 6, n=0,0,0,3	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 5, n=1,1,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 6, n=0,0,0,3	72.7 Dose Intensity (%)	Standard Deviation 17.01
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 6, n=1,1,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 4, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 3, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 5, n=0,0,0,3	93.7 Dose Intensity (%)	Standard Deviation 3.79
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 1, n=0,0,1,7	94.7 Dose Intensity (%)	Standard Deviation 6.75
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 2, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 1, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 2, n=1,5,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 2, n=0,0,1,7	85.0 Dose Intensity (%)	Standard Deviation 17.48
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 5, n=0,1,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 4, n=1,4,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 3, n=1,5,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 3, n=0,0,1,4	79.5 Dose Intensity (%)	Standard Deviation 21.44
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 2, n=1,6,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Cisplatin, Cycle 1, n=2,6,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 1, n=2,5,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	Gemcitabine, Cycle 4, n=0,0,0,4	94.8 Dose Intensity (%)	Standard Deviation 4.11
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 3, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 4, n=1,3,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 4, n=1,2,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 2, n=1,3,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 1, n=1,3,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cis, Gemcitabine, Cycle 3, n=1,4,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Carboplatin, Cycle 5, n=1,1,0,0	NA Dose Intensity (%)	—
28-Day Cycle Eltrombopag 100 mg	Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I	G+Cb, Gemcitabine, Cycle 6, n=1,1,0,0	NA Dose Intensity (%)	—

Secondary

Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II

Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for 21-day cycle was 21 days and for 28-day cycle was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.

Time frame: Cycle 1 to Cycle 6

Population: ITT Population: Participants with at least one period of thrombocytopenia where duration could be calculated.

Arm	Measure	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II	32.6 Days	Standard Deviation 20.31
21-Day Cycle Eltrombopag 100 mg	Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II	23.5 Days	Standard Deviation 18.68

Secondary

Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts

Duration of thrombocytopenia is defined as a period of time in days from the first report of a platelet count with NCI CTCAE Grade 1-4 until the first subsequent report of a platelet count no longer meeting those criteria, regardless of rescue medication usage. It was assessed between Day 1 of Cycle 2 and up to and including any Conclusion/Early Withdrawal visit assigned to the same cycle for participants completing up to 6 cycles, and between Day 1 of Cycle 2 and up to and including the end of Cycle 6 for participants continuing beyond 6 cycles. The chemotherapy cycle for Group A was 21 days and for Group B was 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 2 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 2 to 6.

Time frame: Cycle 2 to Cycle 6

Population: Safety Population. Participants experiencing thrombocytopenia with subsequent increase in platelet count to \>=150Gi/L are included.

Arm	Measure	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts	11.0 Days	Standard Deviation 4.24
21-Day Cycle Eltrombopag 100 mg	Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts	10.6 Days	Standard Deviation 5.63
28-Day Cycle Placebo	Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts	14.7 Days	Standard Deviation 7.77
28-Day Cycle Eltrombopag 100 mg	Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts	13.4 Days	Standard Deviation 5.06

Secondary

Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II

Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 15 scheduled platelet count.

Time frame: Day 15 (averaged across cycles 1 to 6)

Population: ITT Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
21-Day Cycle Placebo	Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II	95.10 Giga (10^9) cells per liter (G cells/L)	Geometric Coefficient of Variation 23.3
21-Day Cycle Eltrombopag 100 mg	Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II	95.29 Giga (10^9) cells per liter (G cells/L)	Geometric Coefficient of Variation 52.1

p-value: 0.80295% CI: [-33.5, 37.4]ANCOVA

Secondary

Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II

Scheduled pre-chemotherapy platelet count is defined within each cycle as the platelet count assessment on which the decision to give or delay chemotherapy was made. This was averaged for each subject across cycles 1 to 6 and a natural log transformation was applied to the average. The log-transformed values were compared between eltrombopag and placebo groups using an analysis of covariance (ANCOVA) model adjusting for cycle duration (21-day vs. 28-day), baseline loge(platelet count) and part of study (part 1 or 2 of phase II). The number of participants analyzed is the number with a Day 8 scheduled platelet count.

Time frame: Day 8 (averaged across cycles 1 to 6)

Population: ITT Population

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
21-Day Cycle Placebo	Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II	162.18 Giga (10^9) cells per liter (G cells/L)	Geometric Coefficient of Variation 74.2
21-Day Cycle Eltrombopag 100 mg	Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II	180.65 Giga (10^9) cells per liter (G cells/L)	Geometric Coefficient of Variation 59.1

p-value: 0.40795% CI: [-15.6, 51.1]ANCOVA

Secondary

Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II

Within-subject platelet count for each par. was calculated by summing up the visit platelet counts from each of Cycles 1 to 6 and dividing it by the number of cycles in which the par. had data. The average within a treatment group was calculated by summing up the values from each par. within the treatment 21-day cycle dividing it by the number of par. These platelet counts are different from the pre-chemotherapy platelet counts for cycles where the chemotherapy dose was delayed. Average within-subject central laboratory platelet count prior to scheduled chemotherapy across Cycles 1 to 6 are summarized. Blood samples were collected on Day 1 and 8 of Cycles 1 to 6 for 21-day cycle and on Day 1, 8 and 15 from Cycles 1 to 6 for 28-day cycle to estimate the average within subject platelet count prior to scheduled chemotherapy. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame: Day 1, Day 8, Day 15 (all averaged across cycles 1 to 6)

Population: ITT Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II	Day1, n=23,48	221.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 128.23
21-Day Cycle Placebo	Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II	Day 8, n=20,42	201.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 143.75
21-Day Cycle Placebo	Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II	Day 15, n=9,22	97.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 24.82
21-Day Cycle Eltrombopag 100 mg	Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II	Day1, n=23,48	272.9 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 120.92
21-Day Cycle Eltrombopag 100 mg	Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II	Day 8, n=20,42	207.4 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 110.93
21-Day Cycle Eltrombopag 100 mg	Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II	Day 15, n=9,22	106.7 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 54.73

Secondary

Number of Participants Requiring a Platelet Transfusion in Phase II

Platelet transfusion was used as a rescue medication for the treatment of thrombocytopenia. Number of participants requiring a platelet transfusion during Cycles 1-6 was summarized and compared between treatment groups using a logistic regression model adjusted for cycle duration. Each cycle included assessments starting at Day 1 of the cycle.

Time frame: Screening, Day -5, throughout cycles 1 to 6 and up to 30 days after IP discontinuation

Population: ITT Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 1	0 Participants
21-Day Cycle Placebo	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 2	2 Participants
21-Day Cycle Placebo	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 3	0 Participants
21-Day Cycle Placebo	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 4	1 Participants
21-Day Cycle Placebo	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 5	0 Participants
21-Day Cycle Placebo	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 6	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 5	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 1	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 4	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 2	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 6	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants Requiring a Platelet Transfusion in Phase II	Cycle 3	2 Participants

Secondary

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II

AE is any untoward medical occurrence temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a MP. For marketed MPs, this also includes failure to produce expected benefits, abuse, or misuse. SAE event is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect.

Time frame: From first dose of investigational product (IP) until 30 days after discontinuation of IP (Longer for AEs related to study participation)

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any SAE Pre Therapy	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Neutopenia On-therapy+30 days	13 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any SAE Post Therapy	2 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Gastrointestinal disorders On-therapy+30 days	12 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any SAE On Therapy+30 days	12 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Blood Creatinine increased On-therapy+30 days	3 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Blood/lymphatic system disorders On-therapy+30 day	21 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Vascular discorders On-therapy+30 days	2 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any AE On Therapy+30 days	23 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Cardiac disorders On-therapy+30 days	1 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Thrombocytopenia On-therapy+30 days	11 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Pulmonary embolism On-therapy+30 days	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any AE Post Therapy	4 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Portal vein thrombosis On-therapy+30 days	1 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Anemia On-therapy+30 days	16 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Deaths On-therapy+30 days	9 Participants
21-Day Cycle Placebo	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any AE Pre Therapy	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Deaths On-therapy+30 days	13 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any AE Pre Therapy	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any SAE Pre Therapy	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any AE On Therapy+30 days	48 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any SAE On Therapy+30 days	16 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any AE Post Therapy	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Any SAE Post Therapy	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Blood/lymphatic system disorders On-therapy+30 day	40 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Thrombocytopenia On-therapy+30 days	19 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Anemia On-therapy+30 days	26 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Neutopenia On-therapy+30 days	21 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Gastrointestinal disorders On-therapy+30 days	25 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Blood Creatinine increased On-therapy+30 days	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Vascular discorders On-therapy+30 days	6 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Cardiac disorders On-therapy+30 days	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Pulmonary embolism On-therapy+30 days	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II	Portal vein thrombosis On-therapy+30 days	0 Participants

Secondary

Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II

The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were further classified into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline is defined as the Day 1 assessment or the latest possible screening assessment. Across Cycles 1-6 included all assessments after first dose of chemotherapy up to the end of Cycle 6. Data exclused for participants taking drugs that affect platelet function or anticoagulants, from the time that the medication was started.

Time frame: Screening, Day -5, Day 1 and 8 of Cycles 1 to 6 of 21-day cycle schedule, Day 1, 8 and 15 of cycles 1 to 6 of 28-day schedule, treatment withdrawal and 30-day follow-up

Population: ITT Population: Participants with at least one visit within the cycle.

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 1	1 Participants
21-Day Cycle Placebo	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 3	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 2	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 4	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 0	11 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 4	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 0	34 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 1	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 2	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II	Grade 3	0 Participants

Secondary

Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II

Dose reductions are required following potential drug-related toxicities. Number of participants with any dose reduction during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only participants who actually received chemotherapy were included for the cisplatin and carboplatin components. All participants were included for the gemcitabine components.

Time frame: Cycle 1 to Cycle 6

Population: ITT Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Cisplatin, 21-day cycle, n=7,9	0 Participants
21-Day Cycle Placebo	Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Carboplatin, 21-day cycle, n=4,12	2 Participants
21-Day Cycle Placebo	Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Gemcitabine, 28-day cycle, n=12,30	8 Participants
21-Day Cycle Placebo	Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Gemcitabine, 21-day cycle, n=11,22	7 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Gemcitabine, 28-day cycle, n=12,30	8 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Carboplatin, 21-day cycle, n=4,12	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Cisplatin, 21-day cycle, n=7,9	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Gemcitabine, 21-day cycle, n=11,22	6 Participants

Secondary

Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I

Any delay in a scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants.

Time frame: All time on chemotherapy treatment

Population: Safety Population

Arm	Measure	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I	2 Participants
28-Day Cycle Placebo	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I	2 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I	1 Participants

Secondary

Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II

Any delay in scheduled dose of gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin was evaluated for eltrombopag and placebo treated participants. Number of participants with any delay in dose during 21-day cycle or 28-day cycle, in part 1 or part 2 of the study is summarized and presented. Only those participants who actually received chemotherapy are included for the cisplatin and carboplatin components and all participants are included for the gemcitabine components (represented by n=X,X in the category titles).

Time frame: Cycle 1 to Cycle 6

Population: ITT Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Gemcitabine, 21-day cycle, n=11,22	5 Participants
21-Day Cycle Placebo	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Carboplatin, 21-day cycle, n=4,12	4 Participants
21-Day Cycle Placebo	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Cisplatin, 21-day cycle, n=7,9	1 Participants
21-Day Cycle Placebo	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Gemcitabine, 28-day cycle, n=12,30	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Gemcitabine, 28-day cycle, n=12,30	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Gemcitabine, 21-day cycle, n=11,22	7 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Cisplatin, 21-day cycle, n=7,9	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II	Carboplatin, 21-day cycle, n=4,12	5 Participants

Secondary

Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II

Number of participants with at least 1 assessment of change from Baseline in creatinine, with increase \>=26.5 UMOL/L are presented. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of IP.

Time frame: After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up

Population: Safety Population

Arm	Measure	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II	5 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II	11 participants

Secondary

Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II

A single safety 12-lead ECG was performed using a standard 12-lead ECG machine at screening and 2 to 6 hours post-dose on C1D4. Change in ECG findings were categorized as 'Clinically significant change (CSC): favorable', 'No change or insignificant change' or 'Clinically significant change (CSC): unfavorable' as determined by the investigator. The Baseline value is defined as the value reported immediately prior to the administration of the first dose of investigational product. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame: C1D4

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II	CSC favorable, n=22,45	0 participants
21-Day Cycle Placebo	Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II	No change or insignificant change, n=22,45	20 participants
21-Day Cycle Placebo	Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II	CSC: unfavorable, n=22,45	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II	CSC favorable, n=22,45	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II	No change or insignificant change, n=22,45	42 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II	CSC: unfavorable, n=22,45	1 participants

Secondary

Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II

Hematology parameters with a related NCI CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment, the maximum toxicity grade reached by a participant post-Baseline was summarized. Hematology parameters included Hemoglobin (Hb) increased, Anemia, Lymphocyte count (Lym), platelet count, White Blood Cell count (WBC) and Total Absolute Neutrophil Count (Total ANC). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. participants with missing Baseline value were assumed to have normal Baseline value. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame: After baseline (C1D1), on-treatment and 30 day follow-up

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 4, n=23,52	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 0, n=23,52	23 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 1, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 2, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 3, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 4, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 0, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 1, n=23,52	4 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 2, n=23,52	13 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 3, n=23,52	6 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 4, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 0, n=23,52	22 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 1, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 2, n=23,52	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 3, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 4, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 0, n=23,52	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 1, n=23,52	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 2, n=23,52	8 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 3, n=23,52	9 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 4, n=23,52	2 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade 0, n=23,52	4 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade 1, n=23,52	1 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade2, n=23,52	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade 3, n=23,52	10 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade 4, n=23,52	5 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 0, n=23,52	0 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 1, n=23,52	4 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 2, n=23,52	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 3, n=23,52	6 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 4, n=23,52	10 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 0, n=23,52	4 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 1, n=23,52	3 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 2, n=23,52	8 Participants
21-Day Cycle Placebo	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 3, n=23,52	6 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 0, n=23,52	14 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 2, n=23,52	14 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 0, n=23,52	52 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 1, n=23,52	9 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 1, n=23,52	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 3, n=23,52	16 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 2, n=23,52	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 4, n=23,52	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 3, n=23,52	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 4, n=23,52	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Increased), Grade 4, n=23,52	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 2, n=23,52	9 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 0, n=23,52	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade 0, n=23,52	16 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 1, n=23,52	16 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 1, n=23,52	10 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 2, n=23,52	16 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade 1, n=23,52	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 3, n=23,52	16 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 3, n=23,52	15 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Hb (Anemia), Grade 4, n=23,52	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade2, n=23,52	17 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 0, n=23,52	47 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 3, n=23,52	11 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 1, n=23,52	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade 3, n=23,52	10 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 2, n=23,52	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 4, n=23,52	12 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 3, n=23,52	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Total ANC, Grade 4, n=23,52	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Increased), Grade 4, n=23,52	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	WBC count, Grade 2, n=23,52	17 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 0, n=23,52	7 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Platelet count, Grade 0, n=23,52	7 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II	Lym (Decreased), Grade 1, n=23,52	10 Participants

Secondary

Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II

Clinical chemistry laboratory parameters with a related CTCAE (version 4.0) toxicity grading were summarized by toxicity grade at each scheduled assessment. Worst-case grade change of the laboratory parameters at anytime post-Baseline is presented as Any grade increase, Increase to Grade 3 or Grade 4. Clinical chemistry laboratory parameters included Albumin (Al), creatinine, AST, ALT, ALP, TB, Calcium hypercalcemia (CaHy)/hypocalcemia (CaHo), Glucose hyperglycemia (GluHy)/hypoglycemia (GluHo), Potassium hypernatremia (KHy)/hyponatremia (KHo) and Sodium hypernatremia (NaHy)/hyponatremia (NaHo). The Baseline value is defined as the value reported immediately prior to the administration of the first dose of chemotherapy in Cycle 1. Post-Baseline is defined as any time after the first dose of chemotherapy in Cycle 1 up to and including all follow-up visits. Only those Participant available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame: After baseline (C1D1), on-treatment (collected on days 1 and 8 for subjects on 21-day cycle and on days 1, 8 and 15 for subjects on 28-day cycle) and 30 day follow-up

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	AST, Increase to Grade 3, n=23,52	3 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Al, Increase to Grade 3, n=23,51	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Al, Increase to Grade 4, n=23,51	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALP, Any grade increase, n=23,52	11 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALP, Increase to Grade 3, n=23,52	1 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALP, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALT, Any grade increase, n=23,52	12 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALT, Increase to Grade 3, n=23,52	3 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALT, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	AST, Any grade increase, n=23,52	11 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Al, Any grade increase, n=23,51	10 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	AST, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	TB, Any grade increase, n=23,52	5 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	TB, Increase to Grade 3, n=23,52	3 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	TB, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHy, Any grade increase, n=23,51	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHy, Increase to Grade 3, n=23,51	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHy, Increase to Grade 4, n=23,51	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHo, Any grade increase, n=23,51	3 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHo, Increase to Grade 3, n=23,51	1 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHo, Increase to Grade 4, n=23,51	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Creatinine, Any grade increase, n=23,52	5 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Creatinine, Increase to Grade 3, n=23,52	1 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Creatinine, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHy, Any grade increase, n=23,52	13 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHy, Increase to Grade 3, n=23,52	2 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHy, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHo, Any grade increase, n=23,52	2 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHo, Increase to Grade 3, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHo, Increase to Grade 4, n=23,52	1 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHy, Any grade increase, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHy, Increase to Grade 3, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHy, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHo, Any grade increase, n=23,52	4 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHo, Increase to Grade 3, n=23,52	1 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHo, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHy, Any grade increase, n=23,52	4 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHy, Increase to Grade 3, n=23,52	1 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHy, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHo, Any grade increase, n=23,52	5 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHo, Increase to Grade 3, n=23,52	1 participants
21-Day Cycle Placebo	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHo, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHy, Increase to Grade 3, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Al, Any grade increase, n=23,51	22 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Creatinine, Any grade increase, n=23,52	11 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Al, Increase to Grade 3, n=23,51	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHo, Any grade increase, n=23,52	11 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Al, Increase to Grade 4, n=23,51	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Creatinine, Increase to Grade 3, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALP, Any grade increase, n=23,52	16 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHy, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALP, Increase to Grade 3, n=23,52	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	Creatinine, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALP, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHy, Increase to Grade 3, n=23,52	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALT, Any grade increase, n=23,52	16 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHy, Any grade increase, n=23,52	31 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALT, Increase to Grade 3, n=23,52	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHo, Any grade increase, n=23,52	15 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	ALT, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHy, Increase to Grade 3, n=23,52	3 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	AST, Any grade increase, n=23,52	15 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHo, Increase to Grade 4, n=23,52	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	AST, Increase to Grade 3, n=23,52	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHy, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	AST, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHo, Increase to Grade 3, n=23,52	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	TB, Any grade increase, n=23,52	11 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHo, Any grade increase, n=23,52	4 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	TB, Increase to Grade 3, n=23,52	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHy, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	TB, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHo, Increase to Grade 3, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHy, Any grade increase, n=23,51	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHo, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHy, Increase to Grade 3, n=23,51	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	GluHo, Increase to Grade 4, n=23,52	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHy, Increase to Grade 4, n=23,51	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHo, Increase to Grade 3, n=23,52	4 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHo, Any grade increase, n=23,51	10 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	NaHy, Any grade increase, n=23,52	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHo, Increase to Grade 3, n=23,51	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	KHy, Any grade increase, n=23,52	10 participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II	CaHo, Increase to Grade 4, n=23,51	0 participants

Secondary

Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count

As per the CTCAE version 4.0, par. with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; par. with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; par. with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and par. with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate thrombocytes at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Par. experiencing thrombocytopenia (Platelets \<150Gi/L) at least once within a cycle are presented in the category title as n=X,X,X,X.

Time frame: Cycle 1 to Cycle 6

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 4, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 2, n=3,9,4,10	0 Participants
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 0 / None, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 3, n=3,9,4,10	1 Participants
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 1, n=3,9,4,10	0 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 3, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 4, n=3,9,4,10	2 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 0 / None, n=3,9,4,10	1 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 2, n=3,9,4,10	3 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 1, n=3,9,4,10	2 Participants
28-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 3, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 1, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 2, n=3,9,4,10	1 Participants
28-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 4, n=3,9,4,10	0 Participants
28-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 0 / None, n=3,9,4,10	1 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 4, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 2, n=3,9,4,10	4 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 1, n=3,9,4,10	3 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 3, n=3,9,4,10	0 Participants
28-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count	Grade 0 / None, n=3,9,4,10	3 Participants

Secondary

Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II

As per the CTCAE version 4.0, participants with a platelet count \<LLN but \>=75 x 10\^9/L (Gi/L) were considered to have Grade 1 thrombocytopenia; participants with a platelet count \<75Gi/L, but \>=50Gi/L were considered to have Grade 2 thrombocytopenia; participants with a platelet count \<50Gi/L, but \>=25Gi/L were considered to have Grade 3 thrombocytopenia and participants with a platelet count \<25Gi/L were considered to have Grade 4 thrombocytopenia. Blood samples were collected to estimate thrombocytes at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Participants experiencing thrombocytopenia(Platelets \<150Gi/L) at least once within cycle are presented in the category title as n=X,X.

Time frame: Cycle 1 to Cycle 6

Population: ITT Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	Grade 2	3 Participants
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	Grade 4	8 Participants
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	Grade 3	8 Participants
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	None	0 Participants
21-Day Cycle Placebo	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	Grade 1	4 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	None	5 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	Grade 1	9 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	Grade 2	9 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	Grade 3	15 Participants
21-Day Cycle Eltrombopag 100 mg	Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II	Grade 4	12 Participants

Secondary

Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II

ECOG-Zubrod scores for the Performance Status were defined as follows: 0: Fully active, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2: Ambulatory and capable of all self-care but unable to carry out any work activities, 3: Capable of only limited self-care, 4: Completely disabled, 5 and Unknown: Dead. The data is presented for the participants with the ECOG performance score at different time points during the study. Only those participants available at the indicated time points were analyzed (represented by n=X,X in the category titles).

Time frame: Screening, C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1 and C17D1

Population: Safety Population

Arm	Measure	Group	Value (NUMBER)
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	Screening, Score 0, n=23,52	3 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	Screening, Score 1, n=23,52	19 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	Screening, Score 2, n=23,52	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C1D1, Score 0, n=23,49	4 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C1D1, Score 1, n=23,49	17 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C1D1, Score 2, n=23,49	0 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C1D1, Unknown, n=23,49	2 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C2D1, Score 0, n=19,36	4 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C2D1, Score 1, n=19,36	13 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C2D1, Score 2, n=19,36	2 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C3D1, Score 0, n=13,27	3 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C3D1, Score 1, n=13,27	9 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C3D1, Score 2, n=13,27	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C4D1, Score 0, n=11,19	4 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C4D1, Score 1, n=11,19	7 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C4D1, Score 2, n=11,19	0 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C5D1, Score 0, n=6,12	2 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C5D1, Score 1, n=6,12	4 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C5D1, Score 2, n=6,12	0 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C6D1, Score 0, n=6,7	2 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C6D1, Score 1, n=6,7	4 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C7D1, Score 0, n=3,2	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C7D1, Score 1, n=3,2	2 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C8D1, Score 0, n=2,1	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C8D1, Score 1, n=2,1	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C9D1, Score 1, n=2,1	2 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C10D1, Score1 n=2,0	2 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C11D1, Score 1, n=2,0	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C11D1, Score 2, n=2,0	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C12D1, Score 1, n=2,0	2 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C13D1, Score 0, n=2,0	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C13D1, Score 1, n=2,0	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C14D1, Score 0, n=2,0	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C14D1, Score 1, n=2,0	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C15D1, Score 1, n=2,0	2 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C16D1, Score 0, n=1,0	1 participants
21-Day Cycle Placebo	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C17D1, Score 2, n=1,0	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C5D1, Score 2, n=6,12	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	Screening, Score 0, n=23,52	19 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C14D1, Score 0, n=2,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	Screening, Score 1, n=23,52	32 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C6D1, Score 0, n=6,7	3 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	Screening, Score 2, n=23,52	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C11D1, Score 2, n=2,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C1D1, Score 0, n=23,49	20 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C6D1, Score 1, n=6,7	4 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C1D1, Score 1, n=23,49	28 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C17D1, Score 2, n=1,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C1D1, Score 2, n=23,49	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C7D1, Score 0, n=3,2	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C1D1, Unknown, n=23,49	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C12D1, Score 1, n=2,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C2D1, Score 0, n=19,36	16 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C7D1, Score 1, n=3,2	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C2D1, Score 1, n=19,36	18 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C14D1, Score 1, n=2,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C2D1, Score 2, n=19,36	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C8D1, Score 0, n=2,1	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C3D1, Score 0, n=13,27	9 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C13D1, Score 0, n=2,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C3D1, Score 1, n=13,27	16 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C8D1, Score 1, n=2,1	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C3D1, Score 2, n=13,27	2 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C16D1, Score 0, n=1,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C4D1, Score 0, n=11,19	8 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C9D1, Score 1, n=2,1	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C4D1, Score 1, n=11,19	10 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C13D1, Score 1, n=2,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C4D1, Score 2, n=11,19	1 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C10D1, Score1 n=2,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C5D1, Score 0, n=6,12	5 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C15D1, Score 1, n=2,0	0 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C5D1, Score 1, n=6,12	6 participants
21-Day Cycle Eltrombopag 100 mg	Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II	C11D1, Score 1, n=2,0	0 participants

Secondary

Platelet Count Nadir for Each Chemotherapy Cycle in Phase I

Platelet nadir is defined as the lowest platelet count (from central laboratory data) reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet nadir count at the following time points: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 and 2, at Days 1, 4, 8, 15 and 17 of Cycle 3 to 6. Group B; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

Time frame: Cycle 1 to Cycle 6

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1, n=3,9,4,10	30.67 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 20.404
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 2, n=2,9,4,10	66.00 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 9.899
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 3, n=2,7,2,7	47.00 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 4.243
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 4, n=2,6,1,7	76.50 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 4.95
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 5, n=1,2,1,4	14.00 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 6, n=1,1,1,4	24.00 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 6, n=1,1,1,4	13.00 Giga (10^9) cells per liter (G cells/L)	—
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 4, n=2,6,1,7	87.50 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 79.173
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1, n=3,9,4,10	106.56 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 113.338
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 3, n=2,7,2,7	88.29 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 71.807
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 2, n=2,9,4,10	122.44 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 115.794
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 5, n=1,2,1,4	148.00 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 182.434
28-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 2, n=2,9,4,10	103.50 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 62.952
28-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 3, n=2,7,2,7	78.50 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 43.134
28-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 4, n=2,6,1,7	86.00 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 6, n=1,1,1,4	110.00 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 5, n=1,2,1,4	75.00 Giga (10^9) cells per liter (G cells/L)	—
28-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1, n=3,9,4,10	60.50 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 22.664
28-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 5, n=1,2,1,4	113.25 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 34.683
28-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 6, n=1,1,1,4	122.75 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 63.163
28-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 2, n=2,9,4,10	135.50 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 73.951
28-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 4, n=2,6,1,7	142.86 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 91.908
28-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 1, n=3,9,4,10	99.00 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 75.7
28-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase I	Cycle 3, n=2,7,2,7	151.00 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 111.946

Secondary

Platelet Count Nadir for Each Chemotherapy Cycle in Phase II

Platelet nadir is defined as the lowest platelet count reported after the first dose of chemotherapy within each cycle. Platelet count nadir is defined for each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Day 1, Day 4, Day 8, Day 15 and Day 17 of Cycles 1 to 6. 28-day cycle; Day 1, Day 4, Day 8, Day 15, Day 22, Day 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).

Time frame: Cycle 1 to Cycle 6

Population: ITT Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 1, n=23,48	68.3 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 47.74
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 2, n=19,37	61.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 35.82
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 3, n=13,26	71.6 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 53.8
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 4, n=11, 19	89.7 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 116.73
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 5, n=6,11	51.7 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 12.23
21-Day Cycle Placebo	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 6, n=5,5	69.6 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 62.76
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 5, n=6,11	83.0 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 58.63
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 1, n=23,48	77.2 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 76.43
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 4, n=11, 19	86.9 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 56.11
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 2, n=19,37	68.5 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 48.92
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 6, n=5,5	136.6 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 151.88
21-Day Cycle Eltrombopag 100 mg	Platelet Count Nadir for Each Chemotherapy Cycle in Phase II	Cycle 3, n=13,26	84.7 Giga (10^9) cells per liter (G cells/L)	Standard Deviation 60.03

Secondary

Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II

Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. The time taken to reach platelet nadir is defined within each cycle. Blood samples were collected to estimate platelet nadir count at the following time points: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22 and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X).

Time frame: Cycle 1 to Cycle 6

Population: ITT Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 5, n=6,11	15.5 Days	Standard Deviation 6.38
21-Day Cycle Placebo	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 3, n=13,26	15.8 Days	Standard Deviation 5.64
21-Day Cycle Placebo	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 6, n=5,5	13.6 Days	Standard Deviation 7.37
21-Day Cycle Placebo	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 2, n=19,37	15.1 Days	Standard Deviation 4.41
21-Day Cycle Placebo	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 7,n=2,2	15.0 Days	Standard Deviation 0
21-Day Cycle Placebo	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 8, n=2,1	12.5 Days	Standard Deviation 3.54
21-Day Cycle Placebo	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 4, n=11,19	15.4 Days	Standard Deviation 5.48
21-Day Cycle Placebo	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 9, n=2,0	12.5 Days	Standard Deviation 3.54
21-Day Cycle Placebo	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 1, n=23,48	14.7 Days	Standard Deviation 4.85
21-Day Cycle Eltrombopag 100 mg	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 9, n=2,0	NA Days	—
21-Day Cycle Eltrombopag 100 mg	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 1, n=23,48	15.7 Days	Standard Deviation 6.12
21-Day Cycle Eltrombopag 100 mg	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 2, n=19,37	15.4 Days	Standard Deviation 3.62
21-Day Cycle Eltrombopag 100 mg	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 3, n=13,26	14.3 Days	Standard Deviation 4.76
21-Day Cycle Eltrombopag 100 mg	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 4, n=11,19	14.7 Days	Standard Deviation 5.19
21-Day Cycle Eltrombopag 100 mg	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 5, n=6,11	13.8 Days	Standard Deviation 4.45
21-Day Cycle Eltrombopag 100 mg	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 6, n=5,5	10.4 Days	Standard Deviation 6.31
21-Day Cycle Eltrombopag 100 mg	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 8, n=2,1	8.0 Days	—
21-Day Cycle Eltrombopag 100 mg	Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II	Cycle 7,n=2,2	7.5 Days	Standard Deviation 0.71

Secondary

Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts

Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. Time to recovery (TR) (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. For Group A, the chemotherapy cycle consisted of 21 days and for Group B, the chemotherapy cycle consisted of 28 days. Blood samples were collected to estimate platelet count at: Group A; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. Group B; Days 1, 4, 8, 15, 22, and 24 of Cycles 1 to 6. Only those participants available at indicated time points were analyzed (represented by n=X, X, X, X).

Time frame: Cycle 1 to Cycle 6

Population: Safety Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 4, n=1,4,1,4	8.0 Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 6, n=0,0,1,0	NA Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 2, n=2,4,3,5	6.5 Days	Standard Deviation 2.12
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 1, n=3,6,4,7	5.3 Days	Standard Deviation 0.58
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 3, n=1,6,1,5	7.0 Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 3, n=1,4,0,2	7.0 Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 4, n=1,4,1,2	2.0 Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 2, n=2,5,3,4	6.5 Days	Standard Deviation 2.12
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 5, n=1,0,1,3	5.0 Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 5, n=1,1,1,1	5.0 Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 6, n=0,1,0,0	NA Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 1, n=3,7,4,8	5.3 Days	Standard Deviation 0.58
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 2, n=2,5,3,4	6.6 Days	Standard Deviation 3.65
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 1, n=3,7,4,8	7.6 Days	Standard Deviation 2.57
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 4, n=1,4,1,2	6.5 Days	Standard Deviation 5.2
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 3, n=1,6,1,5	8.0 Days	Standard Deviation 2.97
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 4, n=1,4,1,4	7.8 Days	Standard Deviation 4.27
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 2, n=2,4,3,5	7.8 Days	Standard Deviation 2.99
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 1, n=3,6,4,7	7.2 Days	Standard Deviation 2.56
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 6, n=0,1,0,0	7.0 Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 5, n=1,1,1,1	5.0 Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 3, n=1,4,0,2	8.5 Days	Standard Deviation 3.7
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 6, n=0,0,1,0	NA Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 5, n=1,0,1,3	NA Days	—
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 2, n=2,4,3,5	9.0 Days	Standard Deviation 4.36
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 1, n=3,6,4,7	7.0 Days	Standard Deviation 0
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 2, n=2,5,3,4	6.0 Days	Standard Deviation 4
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 3, n=1,4,0,2	NA Days	—
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 4, n=1,4,1,2	14.0 Days	—
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 5, n=1,1,1,1	9.0 Days	—
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 6, n=0,1,0,0	NA Days	—
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 1, n=3,7,4,8	7.0 Days	Standard Deviation 0
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 3, n=1,6,1,5	7.0 Days	—
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 4, n=1,4,1,4	14.0 Days	—
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 5, n=1,0,1,3	14.0 Days	—
28-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 6, n=0,0,1,0	5.0 Days	—
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 6, n=0,1,0,0	NA Days	—
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 5, n=1,1,1,1	7.0 Days	—
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 1, n=3,6,4,7	7.7 Days	Standard Deviation 2.87
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 4, n=1,4,1,4	8.3 Days	Standard Deviation 3.95
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 4, n=1,4,1,2	5.0 Days	Standard Deviation 2.83
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 3, n=1,4,0,2	6.0 Days	Standard Deviation 1.41
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 6, n=0,0,1,0	NA Days	—
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 5, n=1,0,1,3	4.7 Days	Standard Deviation 2.52
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 2, n=2,4,3,5	9.4 Days	Standard Deviation 4.28
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 1, n=3,7,4,8	8.5 Days	Standard Deviation 3.46
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<100Gi/L to >=100Gi/L), Cycle 2, n=2,5,3,4	7.0 Days	Standard Deviation 5.1
28-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts	TR(<150Gi/L to >=150Gi/L), Cycle 3, n=1,6,1,5	6.2 Days	Standard Deviation 1.1

Secondary

Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II

Platelet nadir is defined within each cycle as the lowest platelet count reported after the Day 1 chemotherapy dose. TR (\>100Gi/L or \>150Gi/L) from platelet nadir is defined within each cycle as the time in days from the platelet nadir to the time at which platelet count returns to \>=100Gi/L or \>=150Gi/L within the same cycle or up to and including Day 1 of the next cycle. For the last cycle in the study, time to recovery was calculated in the same manner but up to and including any Conclusion/Early Withdrawal visit which has been assigned to the same cycle. Blood samples were collected to estimate platelet count at: 21-day cycle; Days 1, 4, 8, 15 and 17 of Cycles 1 to 6. 28-day cycle; Days 1, 4, 8, 15, 22, and 24of Cycles 1 to 6. Time to recover censored if platelet count did not return to \>=100/150 Gi/L. Censored results are excluded from calculation of summary statistics. Only those participants available at indicated time points were analyzed (represented by n=X, X).

Time frame: Cycle 1 to Cycle 6

Population: ITT Population

Arm	Measure	Group	Value (MEAN)	Dispersion
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 1, n=17, 32	8.1 Days	Standard Deviation 3.15
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 1, n=12, 29	9.3 Days	Standard Deviation 3.89
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 2, n=13, 24	9.9 Days	Standard Deviation 3.64
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 2, n=11, 21	10.5 Days	Standard Deviation 4.5
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 3, n=9, 12	10.1 Days	Standard Deviation 5.01
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 3, n=7, 14	10.4 Days	Standard Deviation 5.74
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 4, n=8, 10	10.0 Days	Standard Deviation 5.63
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 4, n=5, 11	10.2 Days	Standard Deviation 6.65
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 5, n=5,6	7.8 Days	Standard Deviation 1.1
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 5, n=2,4	8.0 Days	Standard Deviation 0
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 6, n=2,2	10.5 Days	Standard Deviation 6.36
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 6, n=2,1	10.5 Days	Standard Deviation 6.36
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 7, n=1,1	15.0 Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 7, n=1,1	15.0 Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 8, n=1,1	14.0 Days	Standard Deviation 1.41
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 8, n=1,0	15.0 Days	—
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 9, n=2,	14.0 Days	Standard Deviation 11.31
21-Day Cycle Placebo	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 9, n=0,	NA Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 7, n=1,1	22.0 Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 1, n=17, 32	8.5 Days	Standard Deviation 3.7
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 5, n=2,4	7.3 Days	Standard Deviation 1.5
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 1, n=12, 29	9.1 Days	Standard Deviation 3.26
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 9, n=0,	NA Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 2, n=13, 24	8.3 Days	Standard Deviation 2.56
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 6, n=2,2	8.5 Days	Standard Deviation 0.71
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 2, n=11, 21	9.0 Days	Standard Deviation 3.31
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 8, n=1,1	20.0 Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 3, n=9, 12	8.8 Days	Standard Deviation 3.16
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 6, n=2,1	8.0 Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 3, n=7, 14	9.6 Days	Standard Deviation 3.43
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 9, n=2,	NA Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 4, n=8, 10	10.9 Days	Standard Deviation 4.77
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 7, n=1,1	22.0 Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 4, n=5, 11	10.6 Days	Standard Deviation 5.39
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<150Gi/L to >=150Gi/L), Cycle 8, n=1,0	NA Days	—
21-Day Cycle Eltrombopag 100 mg	Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II	TR(<100Gi/L to >=100Gi/L), Cycle 5, n=5,6	8.8 Days	Standard Deviation 4.79

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II

Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I

Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I

Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I

Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I

Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I

Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II

Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I

Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I

Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I

Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I

Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II

Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I

Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II

Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts

Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II

Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II

Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II

Number of Participants Requiring a Platelet Transfusion in Phase II

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II

Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II

Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II

Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I

Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II

Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II

Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II

Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II

Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II

Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count

Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II

Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II

Platelet Count Nadir for Each Chemotherapy Cycle in Phase I

Platelet Count Nadir for Each Chemotherapy Cycle in Phase II

Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II

Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts

Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II